In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes

被引:109
作者
Hossann, Martin
Wiggenhorn, Michael
Schwerdt, Alenka
Wachholz, Kirsten
Teichert, Nicole
Eibl, Hansjoerg
Issels, Rolf D.
Lindner, Lars H.
机构
[1] Univ Munich, Med Klin 3, Klinikum Grosshadern, Med Ctr,Dept Internal Med 3, D-81377 Munich, Germany
[2] Univ Munich, Dept Pharm, Munich, Germany
[3] Max Planck Inst Biophys Chem, Gottingen, Germany
[4] Natl Res Ctr Environm & Hlth, CCG Hyperthermia, GSF, Munich, Germany
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 2007年 / 1768卷 / 10期
关键词
thermosensitive liposomes; content release rate; hyperthermia; poly(ethylene glycol); phosphatidylglyceroglycerol; doxorubicin;
D O I
10.1016/j.bbamem.2007.05.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, we reported that 1,2-dipalmitoyl-sn-glycero-3-phosphoglyceroglycerol (DPPGOG) prolongs the circulation time of thermosensitive liposomes (TSL). Since the only TSL formulation in clinical trials applies DSPE-PEG2000 and lysophosphatidylcholine (P-lyso-PC), the objective of this study was to compare the influence of these lipids with DPPGOG on in vitro stability and heat-induced drug release properties of TSL. The content release rate was significantly increased by incorporating DPPGOG or P-lyso-PC in TSL formulations. DPPC/DSPC/DPPGOG 50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) did not differ significantly in their release rate of carboxyfluorescein with > 70% being released within the first l Os at their phase transition temperature. Furthermore, DPPC/DSPC/DPPGOG showed an improved stability at 37 degrees C in serum compared to the PEGylated TSL. The in vitro properties of DPPGOG-containing TSL remained unchanged when encapsulating doxorubicin instead of carboxyfluorescein. The TSL retained 89.1 +/- 4.0% of doxorubicin over 3 h at 37 degrees C in the presence of serum. The drug was almost completely released within 120s at 42 degrees C. In conclusion, DPPGOG improves the in vitro properties in TSL formulations compared to DSPE-PEG2000, since it not only increases the in vivo half-life, it even increases the content release rate without negative effect on TSL stability at 37 degrees C which has been seen for DSPE-PEG2000/P-lyso-PC containing TSL. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:2491 / 2499
页数:9
相关论文
共 40 条
[21]  
Lasic D. D., 1993, LIPOSOMES PHYS APPL, P63
[22]   Novel temperature-sensitive liposomes with prolonged circulation time [J].
Lindner, LH ;
Eichhorn, ME ;
Eibl, H ;
Teichert, N ;
Schmitt-Sody, M ;
Issels, RD ;
Dellian, M .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :2168-2178
[23]   INVESTIGATION OF PHASE-TRANSITIONS OF LIPIDS AND LIPID MIXTURES BY HIGH SENSITIVITY DIFFERENTIAL SCANNING CALORIMETRY [J].
MABREY, S ;
STURTEVANT, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1976, 73 (11) :3862-3866
[24]   The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting [J].
Maeda, H .
ADVANCES IN ENZYME REGULATION, VOL 41, 2001, 41 :189-207
[25]   Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review [J].
Maeda, H ;
Wu, J ;
Sawa, T ;
Matsumura, Y ;
Hori, K .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :271-284
[26]   UPTAKE OF ANTINEOPLASTIC AGENTS INTO LARGE UNILAMELLAR VESICLES IN RESPONSE TO A MEMBRANE-POTENTIAL [J].
MAYER, LD ;
BALLY, MB ;
HOPE, MJ ;
CULLIS, PR .
BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 816 (02) :294-302
[27]   Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition [J].
Mills, JK ;
Needham, D .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2005, 1716 (02) :77-96
[28]  
Mills JK, 2004, METHOD ENZYMOL, V387, P82
[29]  
Needham D, 2000, CANCER RES, V60, P1197
[30]   The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors [J].
Needham, D ;
Dewhirst, MW .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 53 (03) :285-305